AmirAli Talasaz

4.2k total citations · 1 hit paper
13 papers, 1.2k citations indexed

About

AmirAli Talasaz is a scholar working on Cancer Research, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, AmirAli Talasaz has authored 13 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 10 papers in Pathology and Forensic Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in AmirAli Talasaz's work include Cancer Genomics and Diagnostics (13 papers), Genetic factors in colorectal cancer (10 papers) and Lung Cancer Treatments and Mutations (8 papers). AmirAli Talasaz is often cited by papers focused on Cancer Genomics and Diagnostics (13 papers), Genetic factors in colorectal cancer (10 papers) and Lung Cancer Treatments and Mutations (8 papers). AmirAli Talasaz collaborates with scholars based in United States, South Korea and Netherlands. AmirAli Talasaz's co-authors include Richard B. Lanman, Stefanie Mortimer, Kimberly C. Banks, Oliver A. Zill, Scott Kopetz, Jeeyun Lee, Eric A. Collisson, Helmy Eltoukhy, René López and Stephen G. Divers and has published in prestigious journals such as PLoS ONE, Cancer and Cancer Research.

In The Last Decade

AmirAli Talasaz

13 papers receiving 1.2k citations

Hit Papers

Analytical and Clinical Validation of a Digital Sequencin... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
    2015 470 citations Richard B. Lanman, Stefanie Mortimer et al. PLoS ONE profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
AmirAli Talasaz United States 11 970 682 620 380 312 13 1.2k
Ryan S. Alden United States 10 1.0k 1.1× 1.2k 1.7× 719 1.2× 264 0.7× 457 1.5× 14 1.5k
Nora Feeney United States 8 959 1.0× 1.1k 1.7× 772 1.2× 245 0.6× 516 1.7× 11 1.5k
Patricia Vasalos United States 11 826 0.9× 562 0.8× 515 0.8× 301 0.8× 359 1.2× 27 1.2k
Stacy L. Mach United States 7 1.0k 1.1× 1.1k 1.6× 664 1.1× 233 0.6× 456 1.5× 13 1.5k
Han Han‐Zhang China 22 409 0.4× 710 1.0× 672 1.1× 240 0.6× 389 1.2× 57 1.1k
Allison O’Connell United States 6 1.1k 1.1× 933 1.4× 659 1.1× 218 0.6× 448 1.4× 9 1.4k
Carmen Say United States 4 734 0.8× 406 0.6× 372 0.6× 201 0.5× 471 1.5× 9 1.0k
Hyunjae R. Kim United States 10 423 0.4× 710 1.0× 458 0.7× 214 0.6× 541 1.7× 16 1.3k
Nicolas Pécuchet France 14 557 0.6× 600 0.9× 612 1.0× 139 0.4× 366 1.2× 31 1.1k
Bryan C. Ulrich United States 11 643 0.7× 447 0.7× 309 0.5× 214 0.6× 251 0.8× 17 819

Countries citing papers authored by AmirAli Talasaz

Since Specialization
Citations

This map shows the geographic impact of AmirAli Talasaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AmirAli Talasaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AmirAli Talasaz more than expected).

Fields of papers citing papers by AmirAli Talasaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AmirAli Talasaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AmirAli Talasaz. The network helps show where AmirAli Talasaz may publish in the future.

Co-authorship network of co-authors of AmirAli Talasaz

This figure shows the co-authorship network connecting the top 25 collaborators of AmirAli Talasaz. A scholar is included among the top collaborators of AmirAli Talasaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AmirAli Talasaz. AmirAli Talasaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Mack, Philip C., Kimberly C. Banks, Carin R. Espenschied, et al.. (2020). Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases. Cancer. 126(14). 3219–3228. 117 indexed citations
2.
Sonpavde, Guru, Neeraj Agarwal, Gregory R. Pond, et al.. (2019). Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer. Cancer. 125(9). 1459–1469. 41 indexed citations
3.
Lam, Vincent K., Hai T. Tran, Kimberly C. Banks, et al.. (2018). Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clinical Lung Cancer. 20(1). 30–36.e3. 32 indexed citations
4.
Schwaederlé, Maria, Ranajoy Chattopadhyay, Shumei Kato, et al.. (2017). Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Research. 77(19). 5419–5427. 89 indexed citations
5.
Strickler, John H., Jonathan M. Loree, Leanne G. Ahronian, et al.. (2017). Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery. 8(2). 164–173. 196 indexed citations
6.
Kim, Seung Tae, Kimberly C. Banks, Se‐Hoon Lee, et al.. (2017). Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology. 1(1). 1–15. 41 indexed citations
7.
Pereira, Allan Andresson Lima, Maria Pia Morelli, Michael J. Overman, et al.. (2017). Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE. 12(8). e0183949–e0183949. 20 indexed citations
8.
Pal, Sumanta K., Darya Chudova, Justin I. Odegaard, et al.. (2017). Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA. Annals of Oncology. 28. v596–v596. 2 indexed citations
9.
Villaflor, Victoria, Rebecca J. Nagy, Kimberly C. Banks, et al.. (2016). Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 7(41). 66880–66891. 48 indexed citations
10.
Sonpavde, Guru, Rebecca J. Nagy, Sooryanarayana Varambally, Richard B. Lanman, & AmirAli Talasaz. (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma. European Journal of Cancer. 60. e5–e5. 3 indexed citations
11.
Ko, Andrew H., Tanios Bekaii‐Saab, Jessica Van Ziffle, et al.. (2015). A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research. 22(1). 61–68. 100 indexed citations
12.
Kim, Seung Tae, Won‐Suk Lee, Richard B. Lanman, et al.. (2015). Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget. 6(37). 40360–40369. 63 indexed citations
13.
Lanman, Richard B., Stefanie Mortimer, Oliver A. Zill, et al.. (2015). Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS ONE. 10(10). e0140712–e0140712. 470 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryan S. Alden Breakdown of academic impact, for papers by Nora Feeney Breakdown of academic impact, for papers by Patricia Vasalos Breakdown of academic impact, for papers by Stacy L. Mach Breakdown of academic impact, for papers by Han Han‐Zhang Breakdown of academic impact, for papers by Allison O’Connell Breakdown of academic impact, for papers by Carmen Say Breakdown of academic impact, for papers by Hyunjae R. Kim Breakdown of academic impact, for papers by Nicolas Pécuchet Breakdown of academic impact, for papers by Bryan C. Ulrich
Rankless by CCL
2026